EpistemisCross-drug interactions of diuretics
The optimal management of diuretics requires knowing their cross-interaction profile with medications with a high prevalence of use in chronic patients. The following matrix summarizes the most relevant interactions:
File
| Concomitant Drug | Affected Diuretic Group | Physiopathological Mechanism | Clinical Consequence and Recommendation |
|---|---|---|---|
| NSAIDs (Indomethacin, Naproxen) | Loop Diuretics and Thiazides | Inhibition of renal synthesis of prostaglandins (PGE2, PGI2), blocking vasodilation of the afferent arteriole and attenuating natriuresis. | Loss of diuretic and antihypertensive efficacy. Increased risk of acute kidney injury (AKI). Monitor urinary volume and pressure. |
| Lithium | Thiazides and Loop Diuretics | Volume depletion strongly stimulates compensatory sodium and lithium reabsorption in the proximal tubule (mediated by the membrane sodium cotransporter). | Severe Lithium toxicity (tremors, ataxia, confusion). Reduce lithium dose by half or temporarily suspend with close monitoring of lithemia. |
| Aminoglycosides (Amikacin, Gentamicin) | Loop Diuretics (Furosemide, Ethacrynic Acid) | Concomitant blockade of the cochlear stria vascularis cotransporter NKCC1 and intralabyrinthine accumulation of the aminoglycoside. | Severe and irreversible synergistic ototoxicity. Avoid concomitant use unless strictly necessary. Monitor the IV infusion rate of the diuretic. |
| Digoxin | Loop Diuretics and Thiazides | Diuretic-induced potassium and magnesium depletion sensitizes and overstimulates the cardiac basolateral Na+/K+-ATPase pump to the glycoside. | Severe ventricular arrhythmias, extrasystoles and digitalis toxicity. Maintain strictly stable plasma potassium levels (4.0 mEq/L). |
| CYP3A4 inhibitors (Itraconazole, Ritonavir) | Eplerenone, Finerenone, Tolvaptan | Metabolic blockade of the main hepatic microsomal clearance pathway of the diuretic, resulting in severe plasma accumulation. | Hyperkalemia or uncontrolled aquaresis. Absolutely contraindicated in eplerenone. Requires close monitoring or change of diuretic. |
| ACEI / ARA-II | Potassium-Sparing Diuretics (Spironolactone) | Blockade of the renin-angiotensin-aldosterone system synergistically reduces distal potassium secretion. | Critical hyperkalemia with ECG changes (peaked T waves). Monitor serum electrolytes a week after starting and periodically. |
Epistemis is educational review material. It is not a medical device, does not diagnose or prescribe treatment, and does not replace formal medical training, current clinical guidelines, or professional clinical judgment.
- System
- Renal and Diuretics
- Cluster
- Advanced Clinical Synthesis